Q & A
Approaching our highly anticipated 2nd Annual Peptides Congress, we spoke with Paul Feldman, Senior Vice President, GlaxoSmithKline and Lyn Jones, Head of Rare Diseases Chemistry, Head of Chemical Biology, Pfizer.
Paul joined Glaxo Pharmaceuticals in 1987 after completing his PhD studies at the University of California, Berkeley. Throughout his career, he has been involved in a variety of drug discovery programs. Paul’s recent achievements include the approval of the HIV integrase inhibitor dolutegravir (Tivicay) in 2013, and the ultra short-acting benzodiazepine, remimazolam entering Phase 2/3 trials in 2012. Paul talked to us about the risks and challenges his group are currently facing.
Click here to read our interview with Paul.
Prior to joining Pfizer, Lyn worked at The Scripps Research Institute, California and was involved in conducting research in the area of chemical biology. His achievements at Pfizer include the delivery of clinical candidates in the areas of HIV, COPD and synthetic vaccines. Lyn will be speaking at the 2nd Annual Peptides Congress in April and has kindly agreed to share his opinion about the ruling trends in the peptides industry.
Click here to read our interview with Lyn.
      
|